What is the Intron Biotechnology Inc. stock price forecast?

Intron Biotechnology Inc. is currently trading at ₩2,580. View real-time AI analysis on Alpha Lenz.

What is Intron Biotechnology Inc. insider trading activity?

View the latest insider trading data for Intron Biotechnology Inc. on Alpha Lenz.

What is Intron Biotechnology Inc.'s P/E ratio?

Intron Biotechnology Inc.'s P/E ratio is -8.9.

Intron Biotechnology Inc.

KRX · 048530

₩2,580-10(-0.39%)Market closed

Ask about Intron Biotechnology Inc.'s future dividend policy...

Alpha Chat Insight

“Intron Biotechnology Inc. trades at a P/E of -8.9 (undervalued) with modest ROE of -11.7%.”

Ask for details →

Company Overview

Intron Biotechnology Inc. is a company specializing in the biotechnology sector, focusing primarily on developing novel antibiotics and diagnostic systems for infectious diseases. Established to address the rising concern of antibiotic resistance, the company plays a pivotal role in the healthcare industry by innovating treatments that target multi-drug resistant bacteria. Intron's research and development efforts extend to viral diseases, contributing to advancements in molecular diagnostics and therapeutic solutions. The company's expertise in genetic analysis and biotechnology is crucial for its role in modern medicine, impacting both public health and pharmaceutical sectors. By developing biopharmaceutical products and diagnostic technologies, Intron Biotechnology Inc. supports global health initiatives and caters to a diverse range of medical needs, reinforcing its significance in the financial markets as a contributor to healthcare innovation.

CEO윤성준, 윤경원(각자대표)

Websitehttps://www.intron.co.kr

SectorHealthcare

IndustryBiotechnology

Employees62

Company Statistics

FY 2025

Profile

₩79,700,735,640Market Cap

₩5,740,240,960Revenue

30.89MShares Out

62Employees

Margins

54.09%Gross

-100.27%EBITDA

-137.69%Operating

-157.37%Pre-Tax

-156.06%Net

Valuation

-8.90P/E

1.14P/B

13.88EV/Sales

-9.62EV/EBITDA

-10.38P/FCF

Growth (CAGR)

-25.72%Rev 3Yr

-33.88%Rev 5Yr

N/AOp Inc 3Yr

N/AOp Inc 5Yr

N/ANet Inc 3Yr

N/ANet Inc 5Yr

Returns

-11.15%ROA

-11.66%ROE

-11.13%ROIC

Financial Health

₩27,663,676,760Cash & Cash Equivalents

₩-23,215,326,310Net Debt

6.37%Debt/Equity

N/AInterest Cov

Alpha Chat Insight

“Intron Biotechnology Inc. trades at a P/E of -8.9 (undervalued) with modest ROE of -11.7%.”

Ask for details →

Frequently Asked Questions

Intron Biotechnology Inc. (ticker: 048530) is a company listed on KRX in the Healthcare sector (Biotechnology). It has approximately 62 employees. Market cap is $79.7B.

The current price is ₩2,580 with a P/E ratio of -8.9x and P/B of 1.14x.

ROE is -11.66% and operating margin is -137.69%. Annual revenue is $5.7B.